Daratumumab+Rd vs Rd in Relapsed or Refractory Multiple Myeloma

• Research type

  Research Study

• Full title

  Phase 3 Study Comparing Daratumumab, Lenalidomide, and Dexamethasone (DRd) vs Lenalidomide and Dexamethasone (Rd) in Subjects With Relapsed or Refractory Multiple Myeloma

• IRAS ID

  151516

• Contact name

  Gordon Cook

• Contact email

  gordoncook@nhs.net

• Sponsor organisation

  Janssen-Cilag International N.V.

• Eudract number

  2013-005525-23

• ISRCTN Number

  n/a

• Clinicaltrials.gov Identifier

  n/a

• REC name

  West Midlands - Edgbaston Research Ethics Committee

• REC reference

  14/WM/0135

• Date of REC Opinion

  24 Apr 2014

• REC opinion

  Favourable Opinion